Trial · NCT05157698
Pharmacological and Behavioral Treatment After Bariatric Surgery
NCT05157698, Phase 3, Completed, Yale University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Pharmacological and Behavioral Treatment After Bariatric Surgery. Trials, record NCT05157698. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05157698
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pharmacological and Behavioral Treatment After Bariatric Surgery
- NCT number
- NCT05157698
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 84 participants, actual
- Lead sponsor
- Yale University
- Conditions
- Obesity
- Interventions
- Naltrexone and Bupropion Combination, Behavioral Weight Loss, Placebo
- First posted
- 2021-12-15
- Last updated
- 2026-09-21
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Body Mass Index (BMI) | Baseline to after the 6-month treatment | BMI is calculated using measured height and weight |
| Primary | Change in Body Mass Index (BMI) | From post-treatment (6-months) to the 12-month follow-up | BMI is calculated using measured height and weight |
| Secondary | Change in Total cholesterol | From baseline at study enrollment to after the 6-month treatment | Total cholesterol will be measured by bloodwork. |
| Secondary | Change in Total cholesterol | From post-treatment (6-months) to the 12-month follow-up | Total cholesterol will be measured by bloodwork. |
| Secondary | Change in HbA1C | From baseline at study enrollment to after the 6-month treatment | HbA1C will be measured by bloodwork. HbA1C |
| Secondary | Change in HbA1C | From post-treatment (6-months) to the 12-month follow-up | HbA1C will be measured by bloodwork. HbA1C |
| Secondary | Change in Glucose | From baseline at study enrollment to after the 6-month treatment | Glucose will be measured by bloodwork. |
| Secondary | Change in Glucose | From post-treatment (6-months) to the 12-month follow-up | Glucose will be measured by bloodwork. |
| Secondary | Change in Loss-of-Control Eating Frequency | From baseline interview at study enrollment to after the 6-month treatment | Loss-of-control eating frequency is a continuous variable of loss-of-control eating episodes .during the past 28 days assessed using the Eating Disorder Examination interview |
| Secondary | Change in Loss-of-Control Eating Frequency | From post-treatment (6-months) to the 12-month follow-up | Loss-of-control eating frequency is a continuous variable of loss-of-control eating episodes during the past 28 days assessed using the Eating Disorder Examination interview. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DK125650 | Behavioral and Pharmacological Treatments to Enhance Weight Outcomes after Metabolic and Bariatric Surgery | IVEZAJ, VALENTINA | YALE UNIVERSITY | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2021 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05157698
GET https://conductscience.org/api/trials/v1/NCT05157698/registered